Werewolf Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
HOWL$0.97-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the and
Condensed Consolidated Statements of Cash Flows (unaudited)
(amounts in thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(52,441) | $(50,115) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 5,032 | 6,918 |
| Depreciation expense | 1,234 | 1,372 |
| Non-cash interest expense | 1,561 | 864 |
| Non-cash lease expense | 579 | 710 |
| Loss on extinguishment of debt | — | 553 |
| Change in fair value of derivative liability | (215) | (1,715) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (117) | 506 |
| Other receivables | — | 886 |
| Accounts payable, accrued expenses and other liabilities | (3,553) | 864 |
| Deferred revenue | — | (1,340) |
| Operating lease liability | (1,348) | (1,439) |
| Net cash used in operating activities | (49,268) | (41,936) |
| Investing activities: | ||
| Purchases of property and equipment | — | (131) |
| Net cash used in investing activities | — | (131) |
| Financing activities: | ||
| Proceeds from at the market offering of common stock, net of issuance costs | 3,621 | 21,095 |
| Proceeds from drawdown of term loans | — | 30,000 |
| Payment of debt issuance costs | — | (673) |
| Repayment of term loan | — | (40,000) |
| Proceeds from issuances under Employee Stock Purchase Plan | 41 | 76 |
| Proceeds from stock option exercises | — | 35 |
| Net cash provided by financing activities | 3,662 | 10,533 |
| Net decrease in cash, cash equivalents and restricted cash and cash equivalents | (45,606) | (31,534) |
| Cash, cash equivalents and restricted cash and cash equivalents—beginning of period | 112,215 | 155,577 |
| Cash, cash equivalents and restricted cash and cash equivalents—end of period | $66,609 | $124,043 |
| Reconciliation of cash, cash equivalents and restricted cash and cash equivalents to the condensed consolidated balance sheets | ||
| Cash and cash equivalents | $65,711 | $122,827 |
| Restricted cash and cash equivalents | 898 | 1,216 |
| Total cash, cash equivalents and restricted cash and cash equivalents | $66,609 | $124,043 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $2,352 | $2,577 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Purchases of property and equipment in accounts payable and accrued expenses | $— | $124 |
| Issuance costs in accounts payable and accrued expenses | $113 | $40 |
| Fair value of derivative liability issued with term loan | $— | $4,450 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.